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Abstract
Background: Curcuminoids of the spice turmeric and their enhanced derivatives have much potential as cancer
treatments. They act on a wide variety of biological pathways, including those regulating cell division and circadian
rhythms. It is known that circadian clocks can modify cancer therapy effectiveness, according to studies aimed at
optimizing treatments based on the circadian cycle. It is therefore important to determine whether treatments with
curcumin or similar chemotherapeutic agents are regulated by circadian timing. Similarly, it is important to
characterize any effects of curcumin on timing abilities of the circadian clocks within cancer cells.
Methods: We examined the circadian clock’s impact on the timing of cell death and cell division in curcumin-
treated C6 rat glioma cells through continuous video microscopy for several days. To evaluate its persistence and
distribution in cancer cells, curcumin was localized within cell compartments by imaging its autofluorescence.
Finally, HPLC and spectroscopy were used to determine the relative stabilities of the curcumin congeners
demethoxycurcumin and bisdemethoxycurcumin that are present in turmeric.
Results: Circadian rhythms in cell death were observed in response to low (5 μM) curcumin, reaching a peak
several hours before the peak in rhythmic expression of mPER2 protein, a major circadian clock component. These
results revealed a sensitive phase of the circadian cycle that could be effectively targeted in patient therapies based
on curcumin or its analogs. Curcumin fluorescence was observed in cell compartments at least 24 h after treatment,
and the two congeners displayed greater stability than curcumin in cell culture medium.
Conclusions: We propose a mechanism whereby curcuminoids act in a sustained manner, over several days,
despite their tendency to degrade rapidly in blood and other aqueous media. During cancer therapy, curcumin or
its analogs should be delivered to tumor cells at the optimal phase for highest efficacy after identifying the
circadian phase of the cancer cells. We confirmed the greater stability of the curcumin congeners, suggesting that
they may produce sustained toxicity in cancer cells and should be considered for use in patient care.
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Background
Curcumin is a promising phytochemical for treating
several cancers. This ingredient of the spice turmeric has
been used to treat several ailments for thousands of
years because of its anti-inflammatory, anti-microbial,
and wound-healing properties [1]. Curcumin’s anti-
cancer properties have much potential when used alone
or in combination with standard chemotherapies or
radiation treatments. It arrests tumor cell proliferation
by inhibiting multiple signal transduction pathways,
interfering with the cell cycle, and inducing apoptosis.
Relative to most agents currently used to target cancer
cells, curcumin is reported to have low toxicity towards
normal cells [2, 3]. The molecular targets of curcumin
and related curcuminoids include several transcription
factors, oncogenes, and signaling proteins engaged in
cancer initiation and progression [4, 5]. For example,
NF-kB (nuclear factor-kB) and AP-1 (activator protein-
1) are constitutively active in cancer cells, and curcumin
enhances apoptosis by blocking signaling pathways that
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rely on these transcription factors [2, 6]. Curcumin has
multiple molecular targets through which it causes cell
toxicity in various types of cancers, including gliomas
[5, 7–16]. Additionally, curcumin used in combination
with cisplatin or doxorubicin, common chemotherapy
drugs, induces apoptosis in glioblastoma cell lines [15].
One weakness of curcumin as a cancer treatment is
its poor bioavailability and rapid degradation in the
body. Nevertheless, the two major congeners in the
turmeric root, demethoxycurcumin (DMC) and bisdeme-
thoxycurcumin (BDMC) may persist longer in tissues than
curcumin. DMC, BDMC, and the major curcumin metab-
olite tetrahydrocurcumin could provide a sustained anti-
cancer effect [17–19].
Another temporal factor influencing the efficacy of
cancer therapies is the circadian rhythm that is promin-
ent in many physiological processes [20, 21]. The circa-
dian timing system generates approximately 24-h
rhythms in the body through autonomous intracellular
circadian clocks, including ones identified in many can-
cer cells [22, 23]. The role of these clocks in cancer is
not yet known, although circadian-regulated proteins
appear to alter tumor growth rate [24–27]. As the mo-
lecular mechanism of circadian clocks is explored in
greater depth, chemotherapy regimens based on circa-
dian rhythms are being developed and tested [28].
The molecular circadian timing within clock cells could
be altered by curcumin treatments. One likely curcumin
target, Bmal1, is a critical gene within the molecular oscil-
lator producing circadian rhythms. Bmal1 is activated by
curcumin through stimulation of PPAR-γ [29, 30]. Studies
also suggest that polyphenols such as curcumin activate
sirtuin 1 (SIRT1), which also regulates circadian rhythms.
SIRT1, a histone deacetylase, indirectly controls the circa-
dian clock by (1) down-regulating NF-kB [31]; (2) inhibit-
ing nuclear localization of the clock protein mPER2
through deacetylation of the tumor suppressor PML [32];
and (3) binding to the CLOCK-BMAL1 dimer, promoting
deacetylation and degradation of mPER2 [33]. Thus,
curcumin could alter circadian rhythms in normal and
cancer cells, although there are no reported effects on the
circadian timing mechanism.
Drug chronotherapy (use of circadian timing to
optimize pharmacokinetics or pharmacodynamics) is an
effective medical approach [34]. Many proteins involved
in drug absorption, metabolism or elimination display
daily oscillations in synthesis or activity. Studies with ro-
dents show differing effects and toxicities from chemother-
apeutic drugs depending on time of day of administration
[35]. Reported circadian regulation of chemotherapeutic
treatments includes anticancer drugs 5-flurouracil, doxo-
rubicin, roscovitine, and platinum complex analogs cis-
platin, carboplatin, and oxaliplatin [36–38]. Some but not
all of these effects likely depend on the ability of circadian
clocks to regulate daily cell division timing. The most e-
ffective time of day when chemotherapies based on curcu-
min should be administered to patients is unknown. In
this study, we identified a phase of the circadian cycle
when a low dose of curcuminoids is most effective at
inducing death of rat glioma cancer cells in vitro, and
we found that circadian rhythms in gene expression
persist at this dosage.
Methods
Cell culture
Rat C6 glioma cells were cultured in Dulbecco's Modified
Eagle Medium (DMEM) containing penicillin (100 units/
ml), streptomycin (100 μg/ml), 10 % fetal bovine serum
(FBS), and no pyruvate or phenol red (complete medium).
Cells were grown in 100-mm tissue culture dishes at
37 °C in 5 % CO2 and were passaged when they were
nearly confluent. Cells were cotransfected with a con-
struct producing a fusion protein of mPER2 and fire-
fly luciferase (mPer2::mPer2:luc) along with CMV::neo
[39]. These bioluminescent reporter gene cells were
used in most experiments.
Bioluminescence assay
C6 cells containing the mPer2::mPer2:luc reporter gene
were seeded (105 cells/dish) in 35-mm tissue culture
dishes and incubated in DMEM medium containing
10 % FBS at 37 °C in 5 % CO2. When the plates were
90-100 % confluent, the cells were washed twice with a
10 mM HEPES-buffered, low-bicarbonate (4.2 mM),
phenol red-free DMEM, designed for use in room air,
combined with 10 % FBS, which was designated as final
medium (FM), After an exchange with FM, cells were
treated with 20 μM forskolin in ethanol (0.01 % v/v) for
2 h to synchronize the cellular circadian clocks. Immedi-
ately before imaging, 0.2 mM of the luciferase substrate
luciferin (Xenogen) was added. For experiments with low-
dose curcumin, 0.2 mM luciferin and 5 μM curcumin
(CUR, Sigma-Aldrich C-1386) were added to the plate
12 h after forskolin treatment. To monitor rhythmic
expression of the clock protein, bioluminescence was
recorded using a Wallac Victor 1420 Multilabel plate
reader (Perkin Elmer). Culture dishes were maintained at
37 °C while readings were taken hourly for 50 to 96 h.
The background noise was subtracted from each reading
and signals were summed across replicate cultures.
Curcumin treatment
To examine circadian rhythms in cell division and cell
death after treatment with different doses of CUR, C6
cells were seeded at a density of 6 x 105 cells in 60-mm
dishes containing complete medium and then grown
overnight to 50 % confluency. They were then given one
of three treatments: 20 μM forskolin for 2 h, forskolin
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for 2 h followed by 5 μM CUR, or forskolin followed by
10 μM CUR, all in FM. For forskolin treatments, cells
were washed twice with FM, medium was exchanged
with the forskolin treatment, and then cells were incu-
bated for 2 h at 37 °C. CUR was dissolved in dimethyl
sulfoxide (DMSO) to make a 25 mM stock solution and
was diluted in FM before the treatment.
Long-term time-lapse cell imaging
To image individual mitotic and apoptotic events a
single field of view of cells maintained in FM and sealed
in a 60-mm dish was captured at 5-min intervals using
time-lapse videography continuously over 4–6 days. The
imaging system consisted of an inverted microscope with
a 20x objective lens, red LED light source, and a digital
color camera. The imaging system was placed inside a
37 °C incubator to maintain ideal culture conditions.
Time-lapse recording software FLIX (Nimisis.com) cap-
tured live cell events, and each image from the time
series was analyzed by eye and with ImageJ software
(National Institutes of Health).
Immunocytochemistry
Immunofluorescence staining was used to identify apop-
totic cells and verify the peak and trough of the circadian
rhythm in apoptotic events. C6 cells were fixed in 100 %
methanol for 5 min and standard immunocytochemistry
methods were used to identify cleaved caspase-3-positive
cells. Anti-cleaved caspase-3 primary antibody (Cell
Signaling) was used at 1:1000 dilution. The samples were
rinsed after overnight incubation at 4 °C, and were then
incubated for 2 h with Alexa488-conjugated, complemen-
tary secondary antibody. For nuclear staining, cells were
stained with Hoechst 33342 (10–20 ng/ml, Invitrogen) for
2 min. Cells were imaged with a DMI3000B inverted
fluorescence microscope (Leica Microsystems), a Rolera
Thunder cooled-CCD camera with a back-thinned, back-
illuminated, electron-multiplying sensor (Photometrics),
X-Light spinning-disk confocal unit (CrestOptics), and a
Spectra X LED light engine (Lumencore) with image
acquisition and processing controlled by Metamorph
software (Molecular Devices). Images were collected
with a 40x objective lens along with standard DAPI
and fluorescein filters. Images were further analyzed
with ImageJ software.
Curcumin localization in C6 cells
For autofluorescence imaging of curcumin, C6 cells were
grown in 35-mm glass-bottom dishes (MatTek) for one
day, treated with 5 μM CUR in DMSO, and incubated at
37 °C. After 1 h or 24 h, cells were washed with FM and
autofluorescence was imaged using standard fluorescein
filters. Images were captured with the confocal fluores-
cence imaging system and a 63x oil immersion lens. After
24 h, additional treated cells were fixed with methanol,
stained with Hoechst, and imaged using DAPI filters.
Spectral analysis of curcumin
The absorption spectrum of 5 μM CUR in final medium
with DMSO was measured with a GENESYS 10S UV–vis
Spectrophotometer. In a second set of measurements,
cells in 60-mm dishes were given 5 μM CUR, medium
was removed 0, 4, 8, 12, 24, 48, 72 and 96 h later, and
spectra were measured (scanning mode 200–600 nm).
Curcumin absorbs maximally near 430 nm.
HPLC analysis
The High Pressure Liquid Chromatography (HPLC)
studies were performed with a Hewlett-Packard (HP)
1050 HPLC system and Chemstation software. The sta-
tionary phase consisted of Zorbax Eclipse Plus column
(Phenyl Hexyl, 4.6 x 150 mm, 95 Å pore size, pH range
2–9, Agilent Technologies, Santa Clara, CA) along with
a compatible Zorbax Eclipse Plus Phenyl Hexyl pre-
column. The mobile phase was 45 % acetonitrile and
55 % buffer at pH 3.0 (1 % acetic acid). The pH was
adjusted with triethanolamine (approximately 0.4 ml/L).
The run time was 15 min, the column was maintained
at 30 °C, flow rate was 1.0 ml/min, injection volume was
10 μl, and detection wavelength was 420 nm. Under
these chromatographic conditions curcumin eluted with
a retention time of 6–9 min. The elution order was
BDMC <DMC < curcumin. For best results the column
was conditioned by running the mobile phase with the
described composition at a flow rate of 1 ml/min for one
hour. The organic modifier and the buffer component
used were HPLC grade.
Standards containing all three curcuminoids (curcu-
min, DMC, and BDMC) were prepared across a concen-
tration range between 0.025 and 10 μg/ml in DMSO.
DMSO was used in the standard curve because of curcu-
min’s limited stability in aqueous buffers at neutral pH.
The standard curve was found to be linear across the
entire range. The limit of detection for all three curcu-
minoids was 0.025 μg/ml, although the limit of quantita-
tion was determined to be 0.1 μg/ml as the accuracy
below 15 % of the theoretical concentration was deemed
unacceptable. The precision of the method remained
below 10 % of the mean at all levels for curcumin, down
to 0.05 μg/ml for DMC, and down to 0.1 μg/ml for
BDMC. The standard curve data are in Additional file 1.
Data analysis
For measurements of circadian rhythms in mPER2
expression, total bioluminescence measurements from
each dish were collected every hour for up to 4 days.
After background subtraction, each time series was
detrended by subtracting a 24-h running average. For
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continuous imaging of mitotic and apoptotic rates the
cell counts taken from each image frame at 5-min inter-
vals were summed into 1-h bins. The average hourly
rates for each day were compared by two-tailed Student’s
t-test and ANOVA. The dominant period within each
averaged time series was found by Fast Fourier Trans-
form (FFT) analysis (Origin, OriginLab). Circular statis-
tics of circadian rhythms in apoptotic and mitotic events
(Rayleigh test for randomness) were performed using
Oriana software (Kovach Computing Services), and the
mean phase vector was used to indicate the phase of
rhythms. Period estimates of rhythms were determined
using the Lomb-Scargle Periodogram MATLAB program
LOMB, FFT, and the Maximum Entropy Method (MEM,
kSpectra Toolkit, SpectraWorks). When multiple peaks
were found by MEM the peak within the circadian range
(19–29 h) was used as the most precise measure of the
circadian rhythm.
Results
Circadian rhythms persist at low curcumin concentrations
The C6 rat glioma cell line was selected to test for an
effect of the circadian clock on curcumin’s anti-cancer
properties because it displays circadian rhythms in
expression of the core circadian clock gene mPer2 in cell
cultures [40] and in tumorsphere cultures [39]. Curcu-
min decreases NF-kB activation, inhibits C6 cell prolifera-
tion, and induces cell death. We treated C6 cells with a
low dose of curcumin (CUR) to cause limited but signifi-
cant cell death over several days while allowing enough
cells to remain for measurements [40]. Also, because
curcumin acts on many intracellular signaling path-
ways [41] it was important to use a dosage that would
not suppress the molecular mechanism of the circa-
dian oscillator.
We used C6 cells stably transfected with a reporter
gene that generates a fusion protein of mPER2 and
firefly luciferase under control by the mPer2 gene pro-
moter [39]. Circadian clock cells in cultures of these
mPer2::mPer2:luc C6 cells were synchronized with a 2-h
forskolin treatment. Starting 12 h later, to allow acute
forskolin effects to subside, medium was exchanged with
medium containing curcumin dissolved in 0.02 or 0.04 %
DMSO for 5 and 10 μM curcumin, respectively. The
DMSO concentration was well below the threshold of
10 % for toxic effects on colon cancer cells [42], and the
threshold of 0.1 %, below which solutions can be injected
safely into the vitreous of the rat eye without affecting
retinal neurons [43]. This pulse of curcumin was intended
to mimic a single delivery of the drug to a cancer patient
either intravenously or intracerebrally. Similar to what
occurs in the body, it was expected to be degraded in vitro
over the next few hours based on the known properties of
curcumin [44, 45].
C6 cell cultures in medium with 10 % FBS are re-
ported to have a 23.5-h circadian rhythm when mea-
sured with a destabilized luciferase reporter gene
controlled by the mPer2 promoter [40]. Similarly, in a
previous study we detected a 25.2-h bioluminescence
rhythm in a C6 culture expressing the mPER2-LUC fu-
sion protein, according to Lomb-Scargle Periodogram
(LS) analysis (p < 0.001) [46]. The mPer2::mPer2:luc C6
cells also expressed circadian rhythms in cultures given
5 μM CUR (Fig. 1a). For cultures treated with 5 μM
CUR the average period was estimated as 24.48 h by LS
(p < 0.001) (Fig. 1b) and 24.47 h by FFT.
Long-term effects of curcumin on mitosis and cell death
Because circadian rhythms persisted after low-dose cur-
cumin treatments, we synchronized the circadian clock
cells in C6 cultures and examined the pattern of individ-
ual mitotic and apoptotic events for any effects from
curcumin or the circadian clock. To determine whether
the 5 μM curcumin treatment was sufficient to produce
anticancer effects on C6, and whether a higher dose
would be more useful for this study, C6 cells were moni-
tored continuously by digital video imaging of cell cul-
tures. To identify ongoing cell division and cell death
Fig. 1 Circadian rhythms in mPer2 clock gene expression persist after treatment with 5 μM curcumin. (a) Signal from the mPer2::mPer2:luc
reporter gene after a forskolin pulse used to synchronize cellular circadian oscillators is shown as the hourly integrated light signal (relative light
units averaged from 4 independent cultures). (b) A significant period of 24.48 h was detected by Lomb-Scargle Periodogram analysis (p < 0.001) is
shown in the frequency spectrum
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events in cultures time-lapse imaging (TLI) was per-
formed using 5-min intervals between frames for up to
5 days, after synchronizing cells with forskolin and then
treating with curcumin 12 h later. All events were
counted from a single field-of-view which represented
the cell events occurring in the dish (Additional file 2).
The culture dish and microscope remained for days in a
sealed incubator without disturbance. During TLI, there
was initially an average of 23.57 ± 7.03 (SD) cells in the
field-of-view (range 18 to 30, n = 15 cultures).
Distinct mitotic and apoptotic events were visible and
counted following exposure to 0, 5, and 10 μM CUR
(Fig. 2). When mitotic events during day 1 of imaging
were compared, 10 μM was significantly more effective
at suppressing cell division than 5 μM (ANOVA, F =
4.537, Fisher post hoc test, p = 0.0148) and the control
(p = 0.0216) (Fig. 2a). The 5 μM group was, however,
not significantly different from the control (p = 0.806).
When the total mitotic events for the first four days
were examined, 10 μM again resulted in a significant
suppression of mitosis (p = 0.0485) relative to control
(0 μM: 62.67 ± 36.439, n = 6; 5 μM: 60.00 ± 30.470, n = 6;
10 μM: 15.00 ± 0.358, n = 3). By day 4 (5th day in culture),
cell confluence in the control dishes limited our ability to
detect cell division events, so they were not counted.
When the apoptotic events occurring in the 0, 5, and
10 μM groups during day 1 were compared, 10 μM pro-
duced significant cell death (F = 18.751, p < 0.001), but not
5 μM (Fig. 2b). However, when total apoptotic events over
days 1–4 were compared (F = 6.398, p = 0.0128) the 5 μM
treatment caused significant cell death (p = 0.00384). Cell
death rates were overall lower in 10 μM-treated cells, and
more cell death occurred in the first day.
Circadian modulation of curcumin effects on mitosis and
cell survival
To determine whether ongoing events of cell division
and cell death in cultures exposed to curcumin are
modulated by circadian timing, we measured the period
and phase of any significant circadian rhythms (Fig. 3).
Because individual events within the field-of-view were
few the data were pooled from all cultures in each
treatment group. According to LS analysis, a signifi-
cant circadian rhythm in mitosis was detected in the
control culture (Table 1). Most rhythms were similarly
identified by FFT.
To provide a more precise estimate of the circadian
period than what LS or FFT can provide we used the
Maximum Entropy Method to find periods with greater
resolution. According to MEM the untreated cultures
displayed an average period of 21.3 h for mitotic events.
This rhythm in cell division was similar to the doubling
time of 22 h reported for C6 cells [47], suggesting that
the forskolin treatment may have synchronized individ-
ual cell cycles. The 10 μM CUR-treated cultures dis-
played a 20.5-h period. Thus, circadian rhythms were
observed in the mitotic events of the control and 10 μM
cultures (Fig. 3a, c), but not in the 5 μM group (Fig. 3b).
In the presence of 5 μM CUR the cell division cycles
and circadian rhythms appeared to be uncoupled.
Mitosis displayed a rhythm of about 15 h, and these
shorter ultradian rhythms (defined here as having pe-
riods less than 18 h) may have resulted from curcumin
acting on cell cycle oscillations. To further test the
periods of these cultures, we analyzed the mitotic events
with FFT, which yielded periods of 21.3 h for the control
group, 15.0 h for 5 μM, and 18.3 h for the 10 μM group.
Apoptotic events occurring in the cell cultures were
analyzed to detect any circadian rhythms. A rhythm with
a period of 18.9 h was detected in the untreated group
(Fig. 3d), which is at the edge of a typical circadian range
of 19–30 h (Table 1). The apoptotic events occurring in
5 μM CUR-treated cells followed a circadian rhythm
with a period of 22.3 h (Fig. 3e). All the period estimates
for this treatment group fell in the circadian range
(Table 1). Circadian rhythms were absent in 10 μM
Fig. 2 Effects of curcumin on mitosis and apoptosis of C6 glioma cells. Suppression of mitotic rate (a) and induction of cell death rate (b) at two
curcumin concentrations. Average hourly rates were imaged in single fields-of-view for 5 days after a forskolin pulse and a single curcumin
treatment
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Fig. 3 (See legend on next page.)
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CUR-treated cells (Fig. 3f ), which instead had an ultra-
dian rhythm of 11–14 h (Table 1). Circadian rhythms in
apoptosis persisted in the 5 but not 10 μM cultures,
indicating that the clock can modulate cell death at the
lower curcumin dosage.
Because mitotic and apoptotic rates appeared to reach
their maxima at different times, we examined this rela-
tionship in the untreated, 5, and 10 μM groups. The
apparent inverse relationship between apoptotic and mi-
totic events was confirmed by a linear correlation test
comparing the two time-series data sets: Pearson’s cor-
relation r values were −0.350, −0.599, and −0.437 for the
0, 5, and 10 μM treatments, respectively (Fig. 3g-i). The
mitotic rate was highest in the untreated group as apop-
totic events were fewer in that group, while the 10 μM
group had lower mitotic rates and higher rates of apop-
tosis during the initial days of treatment.
Along with the period analyses, we also examined the
phase relationships between the mPER2 rhythm shown
in Fig. 1 and the mitotic and apoptotic rhythms. We
applied circular statistics to identify significant clustering
of apoptotic events in curcumin-treated groups over the
first three 24-h cycles of imaging. When examining the
timing of these events relative to the forskolin treatment,
significant clustering was observed at 18.3 and 18.6 h dur-
ing the 2nd and 3rd days of imaging, respectively, in the
5 μM group (Fig. 3j, k). When comparing these phases
with the mPER2 rhythm, they occurred on the rising
phase, about 6 and 11 h before the corresponding circa-
dian peaks in mPER2 protein expression.
There was no significant clustering of cell death
events in the 10 μM group, in agreement with the
loss of circadian periodicity of apoptosis. The phase
of cell deaths in the control group (0 μM) was signifi-
cantly clustered (p < 0.05) on the second day, but the
mean vector was not significantly different from that
of the 5 μM group, indicating that curcumin did not
produce a measurable phase shift of the rhythm (control:
16:24 with a 99 % confidence interval of 12:31 and 20:17 h
on days 2 and 3, respectively; 5 μM: 18:18 with 99 % confi-
dence intervals of 16:34 and 20:03 h on days 2 and 3).
There was no significant clustering of apoptotic or mitotic
events in the remaining groups.
As an additional test of whether cell death events vary
according to the circadian cycle, we quantified the per-
centage of cells expressing activated caspase-3, a late
apoptotic marker [48, 49] in C6 cells given 5 μM CUR.
Three times were selected to coincide with the second
peak, the following trough, and the third peak observed
in the rhythm in apoptosis (Fig. 3e). The three phases
examined showed relative differences in cell death
matching the oscillations in apoptotic events in the time
series (Fig. 4a). The percentage of apoptotic cells was
61.15 ± 0.03 % at the 45th hr and 47.62 ± 0.04 % at the
69th hr, which are both peak phases in the circadian
rhythm of death rate. During the trough phase (57th hr)
the percentage of apoptotic cells declined to 23.50 ±
0.02 %. Visibly, there were more cells stained with anti-
caspase3 antibody at the peak phases (Fig. 4b, I and II)
than at a trough phase (Fig. 4b, III and IV).
Stability and localization of curcuminoids and their
metabolites
Although curcumin is being tested as an anticancer drug
in a number of clinical trials [5, 50], its use is limited
because of fast degradation at neutral and alkaline pH
and poor tissue absorption [51, 52]. Studies have shown
that curcumin is relatively more stable in culture media
containing 10 % fetal bovine serum (FBS), compared to
phosphate buffer or culture media without FBS [53].
Despite the expected loss of curcumin, our TLI data
showed that apoptosis continued for several days after
initial treatment with 5 or 10 μM CUR. Using a spectro-
photometer we found evidence of curcumin in culture
(See figure on previous page.)
Fig. 3 Circadian clock regulation of curcumin efficacy. a-c: Mitotic events in C6 cultures showed circadian rhythms in 0 and 10 μM but not 5 μM
CUR. d-f: Cell death rates (apoptotic events/hr) displayed circadian rhythms in 0 and 5 but not 10 μM CUR (blue circles: events, red line: after
adjacent averaging). g-i: Apoptotic and mitotic rates were inversely correlated as shown by linear regressions. j, k: The phase of cell death events
displayed significant clustering (p < 0.001) in 5 μM CUR on days 2 and 3 (left and right, Z = 14.62 and 7.399 by Rayleigh Test, respectively). Long
arrow indicates phase of mean vector. Short arrow (green) indicates peak of mPER2::LUC rhythm from Fig. 1. The curcumin treatment began at
12:00 AM (0:00) on Day 1. Each dot indicates 2 events






LS FFT MEM LS FFT MEM
0 114 22.6 21.3 21.3 18.8 21.3 18.9
5 135 14.9 15.0 Non-circadian 22.3 23.3 24.4
10 112 18.5 18.3 20.5 11.1 14.2 Non-circadian
All period estimates are in hours. LS: Lomb-Scargle Periodogram, FFT: Fast Fourier Transform, MEM: Maximum Entropy Method. All LS results were significant
(p < 0.001). “Non-circadian” indicates neither of the two most powerful peaks of the frequency spectra fell in the circadian range (19–29).
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media during the days the cells were imaged (Fig. 5). A
standard curve was created at curcumin’s maximal absorb-
ance near 430 nm [54]. Nevertheless, curcumin levels
declined within the first day, becoming nearly undetectable
(Fig. 5a). During the first 24 h, the curcumin declined with
a half-life of about 1.7 h by degrading or entering cells
(Fig. 5a inset). The curcumin levels in media also showed
an unexpected small increase after the second day.
Autofluorescence imaging of curcumin’s cellular dis-
tribution in live cells showed that curcumin is present
in the nucleus one hour after application (Fig. 5b).
Although curcumin levels decreased considerably in
the culture media, curcuminoids were visible in C6
cells for at least 24 h after application (Fig. 5c). The
autofluorescence study was performed in live C6 cells
1 h and 24 h after curcumin treatment. To confirm the
Fig. 4 Expression of activated caspase-3 according to phase of the circadian cycle. a: Percentage of apoptotic cell counts at 45, 57, and 69 h after
adding 5 μM CUR. The relative changes in the percent cell death agreed with the peaks and trough in the circadian rhythm of death rate for cells
treated with 5 μM CUR (red line, from Fig. 3e, shown here for comparison). b: Immunostaining cleaved caspase-3 in apoptotic cells (green) at two
circadian phases, the peak at 45 h (i) and the trough at 57 h (iii), after 5 μM CUR treatment; ii and iv: The same cells merged with Hoechst nuclear
staining (red). Scale bar = 10 μm
Fig. 5 Stability of the 3 curcuminoids in cell culture. Curcumin degraded with a half-life of about 1.7 h in cell culture medium with cells present. a:
Curcumin absorbance in culture medium with C6 cells for 4 days measured with a spectrophotometer. Inset: Absorbance during the first 24 h. b: 5 μM
CUR produced fluorescence in live C6 cells within 1 h after its introduction. Scale bar = 5 μm. c: Curcuminoid fluorescence persisted in cells for at least
24 h (same scale as B). d: A representative HPLC chromatogram showing complete baseline separation of the 3 curcuminoids from cell culture
medium containing 0.3 % DMSO. The first group of merged peaks near 1.6 min represents the chromophoric compounds from the media. The second
peak at 6.45 min is BDMC, the peak at 7.04 min is that of DMC, and the last peak at 7.68 min is that of curcumin. (mAU =milliabsorbance units). This is
the same CUR preparation used for treating the cells. e: HPLC measurements show curcuminoids DMC and BDMC persist longer than curcumin in cell
culture medium and degrade even slower in DMSO. f: HPLC measurements of curcuminoids in culture medium with C6 cells present for 5 days. Inset:
The same data normalized to initial levels. Line colors are as in e.
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nuclear localization of curcumin 24 h after curcumin
treatment, cells were fixed and stained with Hoechst
nuclear stain (Additional file 3). It was observed that
curcumin was present in the nucleus and was concen-
trated in distinct intra-nuclear sites, as described pre-
viously [55].
The curcumin treatment used in the study contained
the additional congeners DMC and BDMC (Fig. 5d),
which may have contributed to the apoptotic or mitotic
effects. The relative amount of curcumin present in the
CUR treatment was similar to that reported by the manu-
facturer (≥65 %). To better understand the potential con-
tributions of the congeners to the cell effects we used
HPLC to measure curcumin, DMC, and BDMC concen-
trations in cell culture medium at 0, 2, 4, 6 and 12 h after
treatment. Samples containing curcuminoids in complete
medium (10 % FBS serum and 0.3 % DMSO) were
preserved at −20 °C in the dark. To prevent further deg-
radation each sample was allowed to thaw before 10 μl
was injected without further purification or delay.
As predicted from previous studies [56], the HPLC
results indicated that curcumin degraded by over 75 %
within 12 h in culture medium at room temperature, but
the two congeners degraded more slowly (Fig. 5e),
around 20 % for DMC and only 8 % for BDMC, suggest-
ing that they could have been responsible for cell death
along with curcumin after the first day of treatment. The
degradation rates of the congeners in DMSO were rela-
tively slower than in culture media (Fig. 5e). Degradation
patterns of the three curcuminoids were also measured
in samples of medium from cultures containing C6 cells
once per day for 4 days after the curcumin treatment
(Fig. 5f ). All conditions of these samples were kept simi-
lar to those of the previous TLI cultures. There was a
rapid decline of curcumin in culture medium during the
first 24 h at 37 °C (to about 15 %). DMC decreased to
about 16 % in the first 24 h of treatment, whereas
BDMC declined to about 28 % (Fig. 5f inset).
Although the culture medium had very little curcu-
min or congener present, the cells retained curcumi-
noids, as shown in Figs. 5b and c, which could have
been responsible for apoptosis and other cellular ef-
fects. To determine whether the medium retains an
anti-cancer property after curcumin levels decline, we
examined C6 cells treated with a conditioned medium
(CM) that was withdrawn from a C6 culture one day
after treatment with 5 μM curcumin (Additional file 4).
Significant cell death or mitotic arrest was not observed
in response to CM treatment.
Discussion
This is the first study to examine the effects of curcumin
on circadian rhythms in cancer cells and whether the
circadian clock is altered by curcumin treatments.
Curcumin impacts several signaling pathways regulating
the intracellular timing cycles generating circadian
rhythms. These targets include STAT, PPARγ, and NFkB
that act on gene expression within the two intercon-
nected molecular timing loops of the circadian oscillator
that generate the rhythm. Nevertheless, the circadian
rhythm in C6 cells persisted following the 5 μM curcu-
min treatment that produced increased cell death days
later. Although this dosage did not arrest the clock, the
10 μm curcumin treatment did produce a loss of any de-
tectable circadian rhythm in apoptosis. The absence of
circadian periodicity at 10 μM could have been caused
by disruption of individual circadian oscillators within
clock cells or the coupling between circadian clocks.
Nevertheless, fast circadian oscillations in mitotic events
persisted.
Perhaps the best explanation for these results is that
the clock regulates cell death by increasing the probabil-
ity of its occurrence at a particular phase of the circa-
dian cycle, but treatment dosages that produce greater
stimulation of the apoptotic pathway mask clock control
of these events. Because the circadian rhythm in BMAL1
activity is considered a major timing output of the
clock, producing rhythms in many genes, we speculate
that it also modulates expression of proteins that de-
grade or transport curcumin [57]. It is unclear why the
circadian rhythm in mitotic events was lost after apply-
ing 5 μM but not 10 μM curcumin. Nevertheless, the
5 μM data did show a pattern resembling a disrupted
population of circadian oscillators, perhaps because of
fragmentation of the previously synchronized cell popu-
lation into two or more rhythmic groups. Both of these
concentrations were below the reported IC50 of 25 μM
for curcumin effects on C6 cells [58], and cells contin-
ued to proliferate during the several days of imaging,
which was our intention.
Curcumin produced a delayed and persistent cell
death well after it was no longer easily detectable in
medium by HPLC or absorbance spectroscopy at the
end of the first day after delivery. There are several pos-
sible mechanisms that can explain this sustained effect:
The initial treatment altered some of the cells in a way
that arrested their cell cycle and caused them to die
much later. Curcumin is known to induce cell death
through mitotic arrest [59], at which point cell death
might begin long after the time when untreated cells
would have divided. Alternatively, the cells may have
continued to divide, but the treatment caused a change
in the viability of the cells that was also present in the
progeny of the treated cells. For example, curcumin can
produce epigenetic alterations that may promote cancer
cell death [60].
Another intriguing possibility is that because curcumin
is lipophilic it was entrapped in cell membranes where it
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was protected from degradation and then released into
the cytosol, perhaps through membrane turnover, thereby
killing cells much later. A similar mechanism was pro-
posed for effects from vanillin, a curcumin degradation
product with weaker anti-cancer properties [61]. This
possibility is supported by the curcumin autofluorescence
we observed in live cells at least 24 h after exposure.
We also considered the possibility that the two conge-
ners of curcumin may have caused the delayed cell death
along with curcumin or in its absence. Both DMC and
BDMC persisted much longer in culture medium than
curcumin, and both are reported to have anti-cancer
effects, as shown in lung cancer cell lines [62, 63]. Cur-
cumin degrades rapidly in blood and perhaps also cere-
brospinal fluid, but the more persistent congeners may
be responsible for the systemic effects reported in some
animal studies [64]. Interestingly, BDMC also inhibits
cancer cell metastasis [65]. DMC was reported to oxidize
more slowly than curcumin at physiological pH, persist-
ing for at least a day, but BDMC was resistant to oxida-
tion [66], suggesting that it may have a more prolonged
effect on C6 cells than the other two curcuminoids. It is
also possible that some or much of the curcumin au-
tofluorescence we and others observed in cell mem-
branes actually originated from the congeners, which
have excitation and emission spectra similar to those
of curcumin [67]. By passing through this cell reser-
voir, the congeners might have produced delayed cell
toxicity. The two curcumin congeners showed greater
stability in DMSO than in cell culture medium sug-
gesting that the nonpolar cell membrane environment
might also protect curcuminoids longer than culture
medium or other aqueous solutions.
Finally, we did not investigate curcumin’s degradation
products in C6 cells, but some of these have known
anti-cancer properties [62, 68, 69]. For example, tetra-
hydrocurcumin is an early product that would be formed
in aqueous media, such as after intravascular injection
[64], and it may have contributed to cell death in the C6
cultures. Similarly, the more lipophilic degradation prod-
ucts may have accumulated in cell membranes, producing
a delayed response. Because the medium conditioned
with C6 cells for 24 h did not increase cell death, any
curcumin, congeners, or degradation products present
in the medium after the first day are not likely to
have had much effect on cell survival. Instead, curcu-
minoids bound to or integrated into cell membranes
are the most likely causal agents.
The C6 mitotic and apoptotic events displayed a signifi-
cant inverse relationship in 0, 5, and 10 μM curcumin,
indicating a coordinated timing between these two prop-
erties in cultures. Circadian clocks can control the cell div-
ision cycle at several checkpoints, most notably through
p21 regulation by the core clock protein BMAL1 [70, 71].
This coupling is, however, variable as shown previously
when the two types of rhythms were manipulated in Lewis
lung carcinoma cells to oscillate with different periods
[72]. Unlike circadian clocks, metabolic and hormonal
signals can readily arrest or initiate mitosis, and the
greater lability of the cell cycle period impairs its ability to
provide accurate timing. Furthermore, the circadian clock
is compensated to maintain a more constant period as
temperature changes. We detected about a 2-h difference
in period between mitotic and apoptotic oscillations in the
control culture suggesting that the two rhythmic processes
are not tightly coupled. Nevertheless, the correlations we
detected indicate that the phase of the cell cycle can pro-
vide an estimate of circadian phase in some cancer cell
types and may be useful for predicting when curcumin is
most effective. In the C6 cultures, cell death was observed
most often when mitotic rates were minimal.
The highest apoptotic rate was about 6–11 h before the
peak of mPER2 expression in C6 cells, suggesting that
there is a time of day when curcumin treatment would be
most effective for treating patients. To use this result to
optimize delivery of curcumin, encapsulated curcumin or
curcumin nanoparticles [73] it will be necessary to predict
the circadian phase of the cancer cells within the tumor.
Additional studies are needed to determine whether hu-
man tumors with a functioning circadian clock are
entrained by the body’s daily rhythms in cortisol, mela-
tonin or other signals, resulting in a predictable maximum
in PER2 expression for timing delivery of curcumin or
similar drugs. However, any daily rhythms in curcumin’s
absorption and degradation also need to be considered.
Curcumin analogs are more stable alternatives to
curcumin [74] and should be tested to determine whether
they too are most effective at this circadian phase. Fur-
thermore, chemically distinct chemotherapeutic agents
that act through pathways blocked by curcumin, such as
NFkB [58], may be most effective at this phase in gliomas
and other cancer cell types. Curcumin’s reported abil-
ity to prevent cancers may also be optimal at the
time of day corresponding with this phase of highest
sensitivity, which may be estimated from PER2 circa-
dian rhythms measured in non-cancer cells of healthy
individuals.
Conclusion
Glioma cells are most vulnerable to the lethal effects of
curcuminoids at a particular phase of the circadian cycle.
Curcuminoids bind to cell membranes and accumulate
in cell nuclei, possibly serving as a reservoir providing
delayed release and sustained anti-cancer effects. Cancer
patient care should include time-of-day curcumin dos-
ing, to exploit the sensitive phase, and should consider
treatment with the curcumin congeners because of their
stability under physiologically relevant conditions.
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